Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Vaccine|May 15, 2003
Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccineScott A Halperin, David Scheifele, Elaine Mills, et al.
Vaccine|December 7, 2023
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccinesKulkanya Chokephaibulkit, Thanyawee Puthanakit, Surasith Chaithongwongwatthana, et al.
Pediatrics|November 5, 2003
Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACTNicole Le Saux, Nicholas J Barrowman, Dorothy L Moore, et al.
Vaccine|June 17, 2023
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant womenThanyawee Puthanakit, Kulkanya Chokephaibulkit, Surasith Chaithongwongwatthana, et al.
The Pediatric Infectious Disease Journal|July 19, 2014
A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of ageFranck Thollot, David Scheifele, Heidemarie Pankow-Culot, et al.
The Pediatric Infectious Disease Journal|May 7, 2008
Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, CanadaJames D Kellner, David Scheifele, Otto G Vanderkooi, et al.
Vaccine|May 12, 2009
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of ageScott A Halperin, Giuseppe Ferrera, David Scheifele, et al.
Vaccine|November 18, 2021
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing ageKulkanya Chokephaibulkit, Thanyawee Puthanakit, Niranjan Bhat, et al.
Pediatrics|December 5, 2003
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impactDanuta M Skowronski, Valencia P Remple, Jane Macnabb, et al.
The Lancet. Infectious Diseases|September 30, 2018
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trialPunnee Pitisuttithum, Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, et al.
Pageof 8